TRAVERE THERAPEUTICS, INC. Payments for Restructuring
TRAVERE THERAPEUTICS, INC. (TVTX) reported Payments for Restructuring of $12.93 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-02-19
- TRAVERE THERAPEUTICS, INC. payments for restructuring for the quarter ending 2024-12-31 was $797.00K.
- TRAVERE THERAPEUTICS, INC. payments for restructuring for the quarter ending 2024-09-30 was $819.00K.
- TRAVERE THERAPEUTICS, INC. payments for restructuring for the quarter ending 2024-06-30 was $811.00K.
- TRAVERE THERAPEUTICS, INC. payments for restructuring for the quarter ending 2024-03-31 was $10.50M.
- TRAVERE THERAPEUTICS, INC. payments for restructuring for fiscal 2024 was $12.93M.
- TRAVERE THERAPEUTICS, INC. payments for restructuring for fiscal 2023 was $0.00.
- TRAVERE THERAPEUTICS, INC. payments for restructuring for fiscal 2018 was $3.31M, a 268.67% increase from fiscal 2017.
- TRAVERE THERAPEUTICS, INC. payments for restructuring for fiscal 2017 was $897.00K.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2024-12-31 | $797.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.62M derived: sum of 2 quarters · filed 2026-02-19 | $2.43M derived: sum of 3 quarters · filed 2026-02-19 | $12.93M 10-K · filed 2026-02-19 |
| 2024-09-30 | $819.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.63M derived: sum of 2 quarters · filed 2024-10-31 | $12.13M 10-Q · filed 2024-10-31 | $12.13M derived: sum of 4 quarters · filed 2025-02-21 |
| 2024-06-30 | $811.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $11.31M 10-Q · filed 2024-08-01 | $11.31M derived: sum of 3 quarters · filed 2025-02-21 | $11.31M derived: sum of 4 quarters · filed 2025-02-21 |
| 2024-03-31 | $10.50M 10-Q · filed 2024-05-06 | $10.50M derived: sum of 2 quarters · filed 2025-02-21 | $10.50M derived: sum of 3 quarters · filed 2025-02-21 | $10.50M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $0.00 derived: sum of 2 quarters · filed 2025-02-21 | $0.00 derived: sum of 3 quarters · filed 2025-02-21 | $0.00 10-K · filed 2025-02-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-06 | |||
| 2018-12-31 | $3.31M 10-K · filed 2019-02-26 | |||
| 2017-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$1.00K derived: sum of 2 quarters · filed 2019-02-26 | $897.00K 10-K · filed 2019-02-26 | |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-07 | $898.00K 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |